Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.56 |
| ▸ | FNTB | P49356 | 1/20 | 0.56 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9128237 | 1.00 | FNTA (0.56) | FNTAFNTBGGPS1 | |
| SCHEMBL9127288 | 0.98 | FNTA (0.53) | FNTAFNTBGGPS1 | |
| SCHEMBL2875241 | 0.93 | FNTA (0.59) | FNTAFNTBGGPS1 | |
| SCHEMBL16079902 | 0.93 | FNTA (0.59) | FNTAFNTBGGPS1 | |
| SCHEMBL8916061 | 0.93 | FNTA (0.59) | FNTAFNTBGGPS1 | |
| SCHEMBL8916855 | 0.91 | FNTA (0.56) | FNTAFNTBGGPS1 | |
| SCHEMBL8916847 | 0.91 | FNTA (0.56) | FNTAFNTBGGPS1 | |
| SCHEMBL5400265 | 0.91 | FNTA (0.56) | FNTAFNTBGGPS1 | |
| SCHEMBL9128584 | 0.86 | — | — | |
| SCHEMBL9129044 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121554-A1 | HMG-COA SECONDARY METABOLITES AND USES THEREOF | EDENSPACE SYSTEMS CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120108632-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2010127313-A1 | HMG-COA SECONDARY METABOLITES AND USES THEREOF | EDENSPACE SYSTEMS CORPORATION (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100120851-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20070232675-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | ALCON MANUFACTURING, LTD. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20020034725-A1 | SENSITIZATION OF CELLS TO RADIATION AND AND CHEMOTHERAPY | NATIONAL INSTITUTES OF HEALTH, THE | 2002-03-21 | — | — | US | disclosed |
| EP-0910385-A4 | SENSITIZATION OF CELLS TO RADIATION AND CHEMOTHERAPY | UNIV PENNSYLVANIA (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0910385-A1 | SENSITIZATION OF CELLS TO RADIATION AND CHEMOTHERAPY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997038697-A1 | SENSITIZATION OF CELLS TO RADIATION AND CHEMOTHERAPY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232675-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | FNTA, PTAR1, RHOA | FNTA 1/4885FNTB 12/4885GGPS1 11/4885 |
| US-20100120851-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | FNTA, PTAR1, RHOA | FNTA 1/4885FNTB 12/4885GGPS1 11/4885 |
| US-20120108632-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | FNTA, PTAR1, RHOA | FNTA 1/4885FNTB 12/4885GGPS1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.